# A Study to Evaluate the Efficacy, Safety and Tolerability of PDNO Infusion in Patients With Pulmonary Hypertension After Cardiopulmonary Bypass Surgery

> **NCT05699486** · PHASE2 · UNKNOWN · sponsor: **Attgeno AB** · enrollment: 12 (estimated)

## Conditions studied

- Pulmonary Hypertension

## Interventions

- **DRUG:** PDNO
- **DRUG:** Sodium chloride (placebo)

## Key facts

- **NCT ID:** NCT05699486
- **Lead sponsor:** Attgeno AB
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-10-23
- **Primary completion:** 2023-12-31
- **Final completion:** 2023-12-31
- **Target enrollment:** 12 (ESTIMATED)
- **Last updated:** 2023-08-01

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05699486

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05699486, "A Study to Evaluate the Efficacy, Safety and Tolerability of PDNO Infusion in Patients With Pulmonary Hypertension After Cardiopulmonary Bypass Surgery". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT05699486. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*